CARY - AAIPharma, a contract research organization, will utilize software from SAS as part of its service offerings for pharmaceutical, medical device and life science firms.
Financial terms were not disclosed.
AAIPharma will utilize SAS Drug Development solutions for clinical data management, biostatistics and other applications.
“SAS has a proven track record in supplying effective, easy-to-use software for the life sciences industry,” said Anne Wiles, AAIPharma senior vice president for Data Systems and Processes. “We’re looking to take advantage of SAS’ expertise and the great working relationship we have already forged to help accelerate and streamline the management and analysis of our clinical trials data.”
AAIPharma, which recently emerged from bankruptcy and went private, is in the midst of a global expansion effort.
SAS Drug Development is used to integrate data and analysis for drug regulatory submission and to explore possible new markets or products.
AAIPharma to Utilize SAS Software for Clinical Trials, Other Services
Copyright 2007 by WRAL.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
- Oncologists need to track costs as well as treatment options, RTI study says
Jul. 4, 2008 - Unimpressed with iPhone 3G speeds? Wait a few months
Jul. 4, 2008 - IBM acquires mainframe rival PSI
Jul. 3, 2008 - Our STEM winner: ‘Changing The World One Problem At A Time’
Jul. 3, 2008 - CEOs initiating change – that’s much harder than identifying the problem
Jul. 3, 2008
- Oncologists need to track costs as well as treatment options, RTI study says
-
- Atlanta financial software firm lands $10.2M in funding
Jul. 3, 2008 - CED lays off five staff members as part of ‘right-sizing’ moves
Jul. 3, 2008 - Patriotism goes mobile – Multimedia content available for download
Jul. 2, 2008 - Alimera, a Georgia-based drug development firm, eyes IPO
Jul. 2, 2008 - Zink and Polaroid’s inkless printers hit stores this Sunday
Jul. 2, 2008
- Atlanta financial software firm lands $10.2M in funding
More from wrallocaltechwire.com
Market Watch


